Member Login

Dr. Johnny Mahlangu

MBBCh, MMed, FCPath

Biography

Dr. Johnny Mahlangu is an accredited clinical hematologist with over 50 peer-reviewed papers, abstracts and presentations in 2018 alone. He is a part of numerous national and international leadership positions in groups that are dedicated to the advancement of haemophilia treatment around the world

Key Publications

  • Johnny Mahlangu. Emicizumab for prevention of bleeds in Haemophilia. Expert Biological Therapies 2019 Jun 13:1-9

  • Johnny Mahlangu, Johannes Oldenburg, Michael Callaghan, Midori Shima, Maria Elisa Mancuso,  Peter Trask, Michael Recht, Claudia Garcia, Ranchi Yang, Michaela Lehle, Harrison Macharia, Elina Ascanius, Gallia G. Levy,6 Rebecca Kruse-Jarres, Sylvia von Mackensen. Health-Related Quality Of Life and Health Status In Persons With Haemophilia A With Inhibitors: A Prospective, Multicenter, Non-Interventional Study (NIS)- Haemophilia 2019 May;25(3):382-391

  • Johnny Mahlangu. Update on extended Half life FIX products. Ther Adv Hematol. 2018 Oct 5;9(11):335-346

  • Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Victor-Jiménez Yuste, Christine Kempton, Christophe Dhalluin, Michael Callaghan, Willen Bujan, Midori Shima, Elina Asikanius, Gallia G. Levy, Rebecca Kruse-Jarres- Emicizumab Prophylaxis in Hemophilia A without Inhibitors- Study NEJM 2018, 379(9): 811-22

  • Johnny Mahlangu, Monica Cerqueira, Alok Srivastava. Emerging therapies- a Global Perspective.Haemophilia. 2018;24(Suppl. 6):15–21

Key Institutions

  • University of Witwatersrand
    Department of Haematology South Africa

  • Charlotte Maxeke Johannesburg Academic Hospital
    Clinical Haematology Ward and Clinical Service
    South Africa

  • National Health Laboratory Service Haematology Laboratory
    Department of Molecular Medicine and Haematology
    South Africa

  • Witts Health Consortium
    Clinical Haematology Research Unit
    South Africa

Current Positions/Chairs

  • Professor of Haematology
    University of Witwatersrand

  • Head of School of Pathology
    Faculty of Health Sciences, University of Witwatersrand

  • Head of Clinical Haematology Ward and Clinical Service
    Charlotte Maxeke Johannesburg Academic Hospital

  • Head of the Main Haematology Diagnostic Section
    Department of Molecular Medicine and Haematology, National Health Laboratory Service Haematology Laboratory

  • Director
    WFH International Training Centre, Johannesburg

  • Director
    Bleeding Disorders Unit/ Haemophilia Comprehensive Care Centre- Charlotte Maxeke Johannesburg Academic Hospital

  • Director
    Clinical Haematology Research Unit, Wits Health Consortium, Parktown, Johannesburg

  • Accredited Clinical Haematologist
    Wits Donald Gordon Medical Centre, Parktown, Johannesburg

Research Interests

  • Dr. Mahlangu’s interests lie in research and development of innovative therapies in bleeding disorders.

  • He has conducted over 70 international studies including major studies in the evolution of current haemophilia therapies.

Achievements

  • South African National Research Foundation B rating (2018)

  • Faculty of Health Sciences Honors Celebration Special Recognition (2018)

  • Colleges of Medicine of South Africa Triennium Service Recognition Certificate (2018)

  • University of Witwatersrand Vice Chancellor Academic Citizenship award (2018)

  • Fellow of the Academy of Medicine of Malaysia(2018)